Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

CHANGE OF CHAIRMAN OF THE BOARD AND CHANGES TO THE COMPOSITION OF BOARD COMMITTEES

CHANGE OF CHAIRMAN OF THE BOARD

The board (the "**Board**") of directors (the "**Directors**") of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces, after consideration and approval by the nomination committee of the Company (the "**Nomination Committee**") and the Board, the following changes to the chairman of the Board with effect from November 18, 2026:

Resignation of Mr. LIU Gexin as the chairman of the Board

Mr. LIU Gexin has resigned as the chairman of the Board in order to better support the ongoing development of the Company and will remain as a non-executive Director of the Company.

Mr. LIU Gexin has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation as the chairman of the Board that needs to be brought to the attention of the shareholders of the Company.

Since the establishment of Sichuan Kelun Pharmaceutical Co., Ltd. (四川科倫藥業股份有限公司) ("**Kelun Pharmaceutical**") in 1996, Mr. LIU Gexin, endowed with extraordinary strategic vision and steadfast entrepreneurship, has steered Kelun from a fledgling startup into a highly specialized and innovative pharmaceutical group covering large volume parenteral, antibiotic intermediates, innovative drugs and the Health and Wellness industry. Over more than three decades of unwavering dedication, Mr. LIU Gexin has consistently upheld the corporate philosophy of "Exploring New Cures with Scientific and Ethical Excellence"

and devoted himself wholeheartedly to industrial upgrading, overcoming environmental challenges, establishing a robust R&D system and global expansion, making irreplaceable and historic contributions to Kelun's high-quality development.

The Board hereby extends its highest respect and sincere gratitude to Mr. LIU Gexin for his long-term dedication, due diligence and unwavering commitment.

Election of Mr. LIU Sichuan as the chairman of the Board

Mr. LIU Sichuan, a non-executive Director of the Company, has been elected by the Board as the chairman of the Board. The Board warmly welcomes Mr. LIU Sichuan to his new role as the chairman of the Board.

The brief biographical details of Mr. LIU Sichuan are set out as follows:

Mr. LIU Sichuan (劉思川) ("**Mr. Liu**"), born in 1984, is a Chinese national with no permanent residence abroad. He serves as a director and general manager of Kelun Pharmaceutical, holding a Master's degree and the professional title of Senior Economist. He was a Deputy to the 12th and 13th Hunan Provincial People's Congress, and a Member of the Standing Committee of the 12th and 13th Sichuan Provincial Committee of the Chinese People's Political Consultative Conference. He has successively served as a Member of the All-China Youth Federation (中華全國青年聯合會), Executive Director of the China Young Volunteers Association (中國青年志願者協會), Director of the 8th Council of the China Guanghua Science and Technology Foundation (中國光華科技基金會), and Executive Member of the All-China Federation of Industry and Commerce. In 2014, he was awarded the "May Day Labour Medal of Hunan Province" ("湖南省五一勞動獎章"). In 2018, he was honored as the "Outstanding Entrepreneur in Hunan Province" ("湖南省優秀企業家") by Hunan Provincial Committee of the CPC and the People's Government of Sichuan Province (中共湖南省委、湖南省人民政府). In 2020, he received the honorary title of the "National Advanced Individual in Fighting the COVID-19" ("全國抗擊新冠肺炎疫情先進個人") issued by CPC Central Committee, The State Council, PRC and the Military Commission of the CPC Central Committee (中共中央、國務院、中央軍委). In 2021, he was named the "4th Outstanding Non-Public Economic Contributor of Business in Socialism with Chinese Characteristics in Hunan Province" (第四屆湖南省非公有制經濟人士優秀中國特色社會主義事業建設者). In 2023, he was awarded the "the 4th Outstanding Contributor to the Development of Socialism with Chinese Characteristics in Sichuan Province" (第四屆四川省優秀中國特色社會主義事業建設者). He concurrently serves as a director of Sichuan Kelun Industry Group Co., Ltd. (四川科倫實業集團有限公司). Mr. Liu is the son of Mr. LIU Gexin.

Mr. Liu has entered into a service contract with the Company, effective from June 20, 2025 until the expiry of the term of office of the fourth session of the Board. According to the service contract, Mr. Liu will not receive any director's fee for serving as a non-executive Director. No additional remuneration will be payable to Mr. Liu for his role as the chairman of the Board. The amount of the director's fee is determined by the Board upon the recommendation of the remuneration committee of the Company (the "**Remuneration Committee**"), by reference to his duties and responsibilities undertaken with the Company and prevailing market conditions.

Save as disclosed in this announcement, Mr. Liu does not hold any other position with the Company or any of its subsidiaries, has not held any directorship in the last three years in other listed public companies and does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company. Mr. Liu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save for the information set out above, there is no other information to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange and there is no other matter which needs to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Liu as the Chairman of the Board.

CHANGES TO THE COMPOSITION OF MEMBERS OF BOARD COMMITTEES

The Board also resolved that with effect from November 18, 2026:

(a) Mr. LIU Gexin, a non-executive Director, ceased to be the chairman and a member of the Nomination Committee, and has been appointed as a member of the Remuneration Committee; and

(b) Mr. LIU Sichuan, a non-executive Director, ceased to be a member of the Remuneration Committee, and has been appointed as a member and the chairman of the Nomination Committee.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Sichuan
Chairman of the Board and Non-executive Director

Hong Kong, November 18, 2026

As at the date of this announcement, the Board comprises Mr. LIU Sichuan as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Gexin, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.